LORI PELOSI: Open Payments
NPI 1649521352 · MILFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$330 in 14 payments from 8 companies in 2025. Trend: 2023 $25 · 2024 $325 · 2025 $330
Food & beverage: $330
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $77 |
| Neurocrine BioSciences, Inc. | 3 | $74 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Vanda Pharmaceuticals Inc. | 1 | $36 |
| Alkermes, Inc. | 2 | $29 |
| Supernus Pharmaceuticals, Inc. | 1 | $29 |
| Lundbeck LLC | 1 | $23 |
| Indivior Inc. | 1 | $15 |
Products named: CAPLYTA, INGREZZA, REXULTI, FANAPT, ARISTADA, Qelbree, SUBLOCADE.
Industry payments across CT — which companies pay providers there.
